Project Grant R01CA315638
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...
- The National Cancer Institute awarded Raiz Diagnostics, Inc. $4.06 million on September 17, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance LymphomaDx, a gene expression diagnostic assay for lymphoma identification and subtyping. LymphomaDx combines chemical ligation probe amplification with a locked machine learning algorithm to diagnose lymphoma from formalin-fixed, paraffin-embedded core needle biopsies without pathology morphology review, delivering...
- The National Cancer Institute awarded The Leland Stanford Junior University $661,135 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support basic and applied research on rewiring oncogenic pathways to induce cell death in chronic lymphocytic leukemia. The funded work, led by investigators Crabtree, Kay, Gray, and Woyach, develops a new class of small molecules called TCIPs (transcriptional/epigenetic chemical inducers of proximity) designed to activate programmed...
- The National Cancer Institute awarded The Leland Stanford Junior University $676,748 under the Cancer Biology Research program (CFDA 93.396) on August 3, 2026, to investigate metabolic drivers of V(D)J diversity in B-cell acute lymphoblastic leukemia and their implications for minimal residual disease detection and relapse prevention. The recipient will conduct three integrated research aims. Aim 1 analyzes high-throughput sequencing immunoglobulin heavy chain data from more than 1,700...
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $368,294 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period September 1, 2025 through August 31, 2028. This award supports the development of next-generation platforms for interrogating T cell receptor (TCR) specificity to identify and detect tumor antigens at the protein level. The project addresses a critical bottleneck in cancer...
- The National Cancer Institute awarded The Leland Stanford Junior University $593,557 on March 18, 2026, under CFDA 93.394 (Cancer Detection and Diagnosis Research) to develop magnetic resonance methods for measuring response to an emerging lipophilic cancer therapy, specifically BPM31510, a coenzyme Q10 lipid nanoemulsion formulation. The research addresses a critical gap in clinical translation: the lack of real-time measurement tools to assess tumor response to this therapeutic agent, which...
- The National Cancer Institute awarded Yale University a $279,018 cooperative agreement on September 1, 2026, to validate a liquid biopsy assay for early detection of non-Hodgkin's lymphoma in people living with HIV under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project conducts analytical and clinical validation of a high-density methyl-seq assay that detects gene silencing patterns associated with NHL through promoter methylation events in circulating cell-free...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded Mayo Clinic $565,423 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate individualized DNA junction-based liquid biopsies for monitoring glioblastoma and high-grade gliomas during and after treatment. The research addresses a clinical gap in glioma surveillance. Current magnetic resonance imaging monitoring using RANO 2.0 criteria lacks sensitivity and specificity for detecting early disease...